| Flavonoids in Cancer and Apoptosis |
72 |
| Gut Microbiota and Cancer: From Pathogenesis to Therapy |
65 |
| Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum |
63 |
| mTOR Pathways in Cancer and Autophagy |
62 |
| Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems |
54 |
| Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells |
52 |
| New Insights into Long Non-Coding RNA MALAT1 in Cancer and Metastasis |
43 |
| Systemic Therapy for Hepatocellular Carcinoma: Latest Advances |
42 |
| Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment |
42 |
| The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship |
41 |
| Tumor-Associated Neutrophils in Cancer: Going Pro |
41 |
| A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer |
41 |
| Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors |
39 |
| Current Perspectives in Cancer Immunotherapy |
38 |
| The p53 Pathway in Glioblastoma |
37 |
| Obesity, Leptin and Breast Cancer: Epidemiological Evidence and Proposed Mechanisms |
37 |
| Platinum Resistance in Ovarian Cancer: Role of DNA Repair |
37 |
| Reactive Oxygen Species in the Tumor Microenvironment: An Overview |
36 |
| Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities |
34 |
| The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance |
34 |
| DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy |
34 |
| Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy |
33 |
| Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study |
33 |
| The Non-Essential Amino Acid Cysteine Becomes Essential for Tumor Proliferation and Survival |
32 |
| Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies |
32 |
| Cell Origins of High-Grade Serous Ovarian Cancer |
32 |
| Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors |
31 |
| Aptamer Therapeutics in Cancer: Current and Future |
30 |
| Aberrant RNA Splicing in Cancer and Drug Resistance |
30 |
| PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging-A Literature Review |
30 |
| Impact of ROS Generated by Chemical, Physical, and Plasma Techniques on Cancer Attenuation |
30 |
| Identification of Novel MicroRNAs and Their Diagnostic and Prognostic Significance in Oral Cancer |
29 |
| The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers |
29 |
| CircSMARCA5 Regulates VEGFA mRNA Splicing and Angiogenesis in Glioblastoma Multiforme Through the Binding of SRSF1 |
28 |
| Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study |
28 |
| Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment |
27 |
| Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy |
27 |
| Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset |
27 |
| YAP/TAZ Activation as a Target for Treating Metastatic Cancer |
27 |
| Hyperthermia: The Optimal Treatment to Overcome Radiation Resistant Hypoxia |
26 |
| Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study |
26 |
| A Review on a Deep Learning Perspective in Brain Cancer Classification |
26 |
| Microenvironmental pH and Exosome Levels Interplay in Human Cancer Cell Lines of Different Histotypes |
26 |
| Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization |
26 |
| Cancer Stem Cells and Radioresistance: DNA Repair and Beyond |
26 |
| Wnt Signaling in Cancer Metabolism and Immunity |
26 |
| Virus-Based Immunotherapy of Glioblastoma |
26 |
| Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer |
26 |
| Are Integrins Still Practicable Targets for Anti-Cancer Therapy? |
26 |
| p21 in Cancer Research |
25 |
